Physician profile
Cb Benway
NPI 1295740744
$10,170.54
in general payments reported to CMS, 2019-2025
27 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,511 · 2022: $3,191 · 2023: $1,423 · 2024: $1,383 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,689.18 | 2021-2025 | |
| Alkermes, INC. | $1,235.58 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $1,067.84 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $997.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $778.35 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $759.95 | 2021-2025 | Caplyta |
| Tris Pharma INC | $664.54 | 2021-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Lundbeck LLC | $502.96 | 2021-2025 | Rexulti |
| Corium, LLC | $477.82 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $407.66 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $292.56 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $229.80 | 2022-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $211.63 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $180.77 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $141.97 | 2024-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $110.64 | 2024 | Relexxii |
| Vanda Pharmaceuticals INC. | $85.69 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $71.33 | 2023 | Quviviq |
| Braeburn INC. | $51.69 | 2023-2024 | Brixadi |
| Tempus Ai, INC | $42.57 | 2024 | Tempus Pixel |
| Janssen Pharmaceuticals, INC | $41.35 | 2025 | Invega Sustenna |
| Collegium Pharmaceutical, INC. | $38.60 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $24.61 | 2022 | |
| Avion Pharmaceuticals | $18.16 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, LP | $16.06 | 2021 | |
| Biogen, INC. | $15.85 | 2023 | |
| Adlon Therapeutics L.P. | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cb Benway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.